- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01568905
Palatability of Experimental Cigarettes - Study 2
30 de octubre de 2019 actualizado por: University of Minnesota
Palatability of Experimental Cigarettes
Smoking remains a leading cause of preventable disease and premature death worldwide.
Approximately 1 out of every 5 deaths is associated with cigarette smoking, and roughly half of all daily smokers will die prematurely from tobacco-related illness.
Reducing the nicotine in cigarettes to the point that they are rendered non-addictive can potentially be an effective public policy measure that can significantly reduce tobacco-related mortality and morbidity by decreasing the initiation of smoking and promoting cessation.
The Family Smoking Prevention and Tobacco Control Act (FSPTCA) enables the FDA to establish tobacco product standards including placing limits on the allowable nicotine content of cigarettes.
Currently, no reduced nicotine cigarettes are available that will allow studying the feasibility of this policy measure.
The National Institute on Drug Abuse has contracted with Research Triangle Institute to assist in the development of cigarettes with varying nicotine content that can be made available to researchers.
They have established a contract that will result in the manufacture of 9 million cigarettes to be distributed to the research community.
Prior to full production, the palatability and nicotine intake of these cigarettes in smokers must be determined.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Phase 3: This descriptive study will use a between subjects, double blind design.
This study will test 3 nicotine levels of nicotine, tar and ventilation.
Subjects and research assistants will be blind to the cigarette type.
Tipo de estudio
Intervencionista
Inscripción (Actual)
36
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55414
- University of Minnesota
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 64 años (Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- 18-64 years old
- Regular smokers (10+ cigarettes per day and has done so for the last year)
- Inhaling when smoking
- Carbon monoxide (CO) > 8 ppm
Exclusion Criteria:
- In the past year, suffered from any cardiovascular disease such as: heart disease, heart attack, stroke or angina, any respiratory diseases such as chronic bronchitis or chronic obstructive pulmonary disease (COPD), any type of cancer
- Currently suffering from Bipolar Disorder, General Anxiety Disorder, Schizophrenia, or a major depressive episode
- Taken any of the following drugs more than twice per week during the past month: antidepressants, anti-anxiety medications.
- Consumed more than 15 alcoholic drinks per week for the past month
- Pregnant, trying to become pregnant, or lactating (assessed by self-report)
- In the past 3 months, used nicotine replacement products (like the patch, gum, or inhaler), or the medications bupropion varenicline
- Currently trying or planning to reduce or quit tobacco use in the next 30 days
- Used other forms of tobacco 10 or more days in the past 30 days
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm 1 Low Level Nicotine Cigarette
(0.4 mg/g)
|
smoke the study cigarette exclusively for one week
|
|
Experimental: Arm 2 Intermediate Nicotine Level Cigarette
(5.7-5.8 mg/g)
|
smoke the study cigarette exclusively for one week
|
|
Experimental: Arm 3 High Level Nicotine Cigarette
(11.4-12.8 mg/g)
|
smoke the study cigarette exclusively for one week
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1
Periodo de tiempo: Second Visit (Week 1) minus Baseline (Day 1)
|
Two urine TNE levels are taken, one at baseline and one at week 1, to assess TNE levels for nicotine exposure.
TNE is the sum of nicotine, cotinine, trans 3'-hydroxycotinine and their respective glucuronide conjugates.
Values reported in nmols/ml.
|
Second Visit (Week 1) minus Baseline (Day 1)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Responses on Modified Cigarette Evaluation Scale
Periodo de tiempo: Baseline usual brand cigarettes (Day 1) compared to when using study cigarettes (Week 1)
|
Modified Cigarette Evaluation Scale [CES] is a 100 mm visual analog scale (0=not at all or very little nicotine; 100=extremely or high in nicotine) of 20 questions assessing different dimensions of responses to usual brand cigarettes (e.g., psychological reward, satisfaction and aversiveness) and includes additional 5 point likert-type questions (definitely agree to definitely disagree) on perceptions of satisfaction and willingness to use the product.
Results satisfaction subscale.
|
Baseline usual brand cigarettes (Day 1) compared to when using study cigarettes (Week 1)
|
|
Change From Baseline of Perceived Health Risk Scale Response to Test Cigarettes
Periodo de tiempo: Baseline (Day 1) Compared to Second Visit (Week 1)
|
Questionnaire: Perceived Health Risk Scale asks subjects to rate their perception of health risks for lung cancer for the study product to which they have been randomly assigned.
This is a 100 mm visual analog scale; 0=very low risk of disease, 100=very high risk of disease.
|
Baseline (Day 1) Compared to Second Visit (Week 1)
|
|
Comparison of Number of Cigarettes Smoked
Periodo de tiempo: 1 week
|
Subjects were given a daily diary to collect the number of study and/or conventional cigarettes they have smoked each day.
Cigarettes smoked (both usual brand and experimental) in a given week were summed over the first 7 reported days.
If the number of cigarettes smoked was missing for 1 day, the average of the other days in that week was used in its place and reported as total number of cigarettes per week.
|
1 week
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Dorothy Hatsukami, Ph.D., Tobacco Use Research Program, University of Minnesota
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de febrero de 2011
Finalización primaria (Actual)
1 de marzo de 2012
Finalización del estudio (Actual)
1 de marzo de 2012
Fechas de registro del estudio
Enviado por primera vez
3 de enero de 2012
Primero enviado que cumplió con los criterios de control de calidad
29 de marzo de 2012
Publicado por primera vez (Estimar)
2 de abril de 2012
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
1 de noviembre de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
30 de octubre de 2019
Última verificación
1 de octubre de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1012M94314
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .